Dengue and dengue hemorrhagic fever: Management issues in an intensive care unit;Dengue e dengue hemorrágico: Aspectos do manejo na unidade de terapia intensiva

Jornal de Pediatria

Volumn 83, Issue SUPPL. 2, 2007, Pages

  Singhi, Sunit ^a   Kissoon, Niranjan ^b   Bansal, Arun ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dengue fever; Fluid infusion; Hemorrhagic shock; Sepsis; Shock

Indexed keywords

DOMPERIDONE; PARACETAMOL;

ACUTE KIDNEY FAILURE; CLINICAL CLASSIFICATION; DENGUE; DENGUE VIRUS; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; EARLY DIAGNOSIS; FLUID RESUSCITATION; HEMORRHAGIC FEVER; HUMAN; INFORMATION RETRIEVAL; INSECT BITE; INTENSIVE CARE UNIT; LIVER FAILURE; MEDLINE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PUBLIC HEALTH PROBLEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEPTIC SHOCK; SYMPTOMATOLOGY; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ANIMALS; CRITICAL CARE; DENGUE; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; FLUID THERAPY; HUMANS; INSECT VECTORS; INTENSIVE CARE UNITS; MOSQUITO CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; SYNDROME;

EID: 34250375219     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1622     Document Type: Review

References (44)

1. World Health Organization. Strengthening implementation of the global strategy for dengue fever and dengue haemorrhagic fever, prevention and control. Report of the informal consultation, 18-20 October 1999. Geneva: WHO; 1999.
2. World Health Organization. Scientific working group on dengue. Meeting report, Geneva, Switzerland, 3-5 April 2000. Geneva: WHO; 2000.
3. Chang GJ. Molecular biology of dengue viruses. In: Dengue and dengue hemorrhagic fever. Gubler DJ, Kuno G, eds. Cambridge: CAB International; 1997. p. 175-98.
4. Feres VC, Martelli CM, Turchi MD, Junior JB, Nogueira RM, Rocha BA, et al. Laboratory surveillance of dengue virus in Central Brazil, 1994-2003. J Clin Virol. 2006;37:179-83.
5. Thavara U, Tawatsin A, Chansang C, Kong-ngamsuk W, Paosriwong S, Boon-Long J, et al. Larval occurrence, oviposition behavior and biting activity of potential mosquito vectors of dengue on Samui Island, Thailand. J Vector Ecol. 2001;26:172-80.
6. Perich MJ, Davila G, Turner A, Garcia A, Nelson M. Behavior of resting Aedes aegypti (culicidae: diptera) and its relation to ultra-low volume adulticide efficacy in Panama City, Panama. J Med Entomol. 2000;37:541-6.
7. Vezzani D, Schweigmann N. Suitability of containers from different sources as breeding sites of Aedes aegypti (L) in a cemetery of Buenos Aires City, Argentina. Mem Inst Oswaldo Cruz. 2002;97:789-92.
8. King CA, Marshall JS, Alshurafa H, Anderson R. Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line. J Virol. 2000;74:7146-50.
9. Hayes EB, Gubler DJ. Dengue and dengue hemorrhagic fever. Pediatr Infect Dis J. 1992;11:311-7.
10. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis. 2002;186:1165-8.
11. Ho Lj, Wang JJ, Shaio MF, Kao CL, Chanq DM, Han SW, et al. Infection of human dendritic cells by denude virus causes cell maturation and cytokine production. J Immunol. 2001;166:1499-506.
12. Chakravarti A, Kumaria R. Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J Med Res. 2006;123:25-30.
13. Lin CF, Lei HY, Shiau AL, Liu HS, Yeh TM, Chen SH, et al. Endothelial cells apoptosis induced by antibodies against dengue virus nonstructural protein I via production of nitric oxide. J Immunol. 2002;169:657-64.
14. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1998;239:476-81.
15. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: WHO; 1997.
16. World Health Organization. Prevention and control of dengue and dengue hemorrhagic fever: comprehensive guidelines. WHO Regional publication, SEARO, No 29, 1999.
17. Campagna D de S, Miagostovich MP, Siqueira MM, Cunha RV. Etiology of exanthema in children in a dengue endemic area. J Pediatr (Rio J). 2006;82:354-8.
18. Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis. 2006;43:1023-30.
19. Pan American Health Organization. Guidelines for the prevention and control of dengue and dengue hemorrhagic fever in the Americas. Washington, DC: PAHO; 1994.
20. Pande JN, Kabra SK. Dengue hemorrhagic fever and dengue shock syndrome. Natl Med J India. 1996;9:256-8.
21. Kabra SK, Jain Y, Pandey RM, Madhulika, Singhal T, Tripathi P, et al. Dengue hemorrhagic fever in children in the 1996 Delhi epidemic. Trans R Soc Trop Med Hyg. 1999:93:294-8.
22. Nimmannitya S. Clinical manifestations of dengue/dengue hemorrhagic fever. In: Monograph on dengue/dengue hemorrhagic fever. New Delhi: WHO; 1993. p. 48-54.
23. Kabra SK, Juneja R, Madhulika, Jain Y, Singhal T, Dar L, et al. Myocardial dysfunction in children with dengue haemorrhagic fever. Natl Med J India. 1998;11:59-61.
24. Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis. 2001;2:33-42.
25. Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, et al. Neurological manifestations of dengue infection. Lancet. 2000;355:1053-9.
26. Soares CN, Faria LC, Peralta JM, de Freitas MR, Puccioni-Sohler M. Dengue infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. J Neurol Sci. 2006;249:19-24.
27. Kalita J, Misra UK, Mahadevan A, Shankar SK. Acute pure motor quadriplegia: is it dengue myositis? Electromyogr Clin Neurophysiol. 2005;6:357-61.
28. Poovorawan Y, Hutagalung Y, Chongsrisawat V, Boudville I, Bock HL. Dengue virus infection: a major cause of acute hepatic failure in Thai children. Ann Trop Paediatr. 2006;26:17-23.
29. Guzman MG, Kouri G. Advances in dengue diagnosis. Clin Diagn Lab Immunol. 1996,3:621-7.
30. Lolekha R, Chokephaibulkit K, Yoksan S, Vanprapar N, Phongsamart W, Chearskul S. Diagnosis of dengue infection using various diagnostic tests in the early stage of illness. Southeast Asian J Trop Med Public Health. 2004;2:391-5.
31. Guidelines for treatment of dengue fever/dengue hemorrhagic fever in small hospitals. Geneva: WHO; 1999.
32. Kamath SR, Ranjit S. Clinical features, complications and atypical manifestations of children with severe forms of dengue hemorrhagic fever in South India. Indian J Pediatr. 2006;73:889-95.
33. Cam BV, Tuan DT, Fonsmark L, Poulsen A, Tien NM, Tuan HM, et al. Randomized comparison of oxygen mask treatment Vs nasal continuous positive airway pressure in dengue shock syndrome with acute respiratory failure. J Trop Pediatr. 2002;6:335-9.
34. Ngo NT, Cao XT, Kneen R, Wills B, Nquyen VM, Chu VT, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis. 2001;32:204-13.
35. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005;353:877-89.
36. Ranjit S, Kissoon N, Jayakumar I. Aggressive management of dengue shock syndrome may decrease mortality rate: a suggested protocol. Pediatr Crit Care Med. 2005;6:412-9.
37. Khongphatthanayothin A, Suesaowalak M, Muangmingsook S, Bhattarkosol P, Pancharoen C. Hemodynamic profiles of patients with dengue hemorrhagic fever during toxic stage: an echocardiographic study. Intensive Care Med. 2003;4:570-4.
38. Halstead SB. Dengue. Curr Opin Infect Dis. 2002;5:471-6.
39. Lum LC, Goh AY, Chan PW, El-Amin AL, Lam SK. Risk factors for hemorrhage in severe dengue infections. J Pediatr. 2002;5:629-31.
40. Kabra SK, Jain Y, Madhulika, Tripathi P, Singhal T, Broor S, et al. Role of platelet transfusion in dengue hemorrhagic fever. Indian Pediatr. 1998;35:452-4.
41. Tassniyom S, Vaanawathan S, Chirawatkal V, Rojanasuphot S. Failure of high dose methylprednisolone in established dengue shock syndrome: a placebo controlled double blind study. Pediatrics. 1993;92:111-5.
42. Monath T, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, et al. Clinical proof of principle for ChimeriVax TM: recombinant live, attenuated vaccines against Flavivirus infections. Vaccine. 2002;20:1004-18.
43. Anez G, Balza R, Valero N, Larreal Y. Economic impact of dengue and dengue hemorrhagic fever in the State of Zulia, Venezuela, 1997-2003. Rev Panam Salud Publica. 2006;19:314-20.
44. Halstead SB, Lan NT, Myinet TT, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerging Infect Dis. 2002;8:1474-9.